| 1. |
|
|
| 2. |
- Vaivads, Andris, et al.
(author)
-
Turbulence Heating ObserveR - satellite mission proposal
- 2016
-
In: JOURNAL OF PLASMA PHYSICS. - 0022-3778. ; 82
-
Journal article (peer-reviewed)abstract
- The Universe is permeated by hot, turbulent, magnetized plasmas. Turbulent plasma is a major constituent of active galactic nuclei, supernova remnants, the intergalactic and interstellar medium, the solar corona, the solar wind and the Earth's magnetosphere, just to mention a few examples. Energy dissipation of turbulent fluctuations plays a key role in plasma heating and energization, yet we still do not understand the underlying physical mechanisms involved. THOR is a mission designed to answer the questions of how turbulent plasma is heated and particles accelerated, how the dissipated energy is partitioned and how dissipation operates in different regimes of turbulence. THOR is a single-spacecraft mission with an orbit tuned to maximize data return from regions in near-Earth space - magnetosheath, shock, foreshock and pristine solar wind - featuring different kinds of turbulence. Here we summarize the THOR proposal submitted on 15 January 2015 to the 'Call for a Medium-size mission opportunity in ESAs Science Programme for a launch in 2025 (M4)'. THOR has been selected by European Space Agency (ESA) for the study phase.
|
|
| 3. |
|
|
| 4. |
- Le Contel, O., et al.
(author)
-
Lower Hybrid Drift Waves and Electromagnetic Electron Space-Phase Holes Associated With Dipolarization Fronts and Field-Aligned Currents Observed by the Magnetospheric Multiscale Mission During a Substorm
- 2017
-
In: Journal of Geophysical Research - Space Physics. - : AMER GEOPHYSICAL UNION. - 2169-9380 .- 2169-9402. ; 122:12, s. 12236-12257
-
Journal article (peer-reviewed)abstract
- We analyze two ion scale dipolarization fronts associated with field-aligned currents detected by the Magnetospheric Multiscale mission during a large substorm on 10 August 2016. The first event corresponds to a fast dawnward flow with an antiparallel current and could be generated by the wake of a previous fast earthward flow. It is associated with intense lower hybrid drift waves detected at the front and propagating dawnward with a perpendicular phase speed close to the electric drift and the ion thermal velocity. The second event corresponds to a flow reversal: from southwward/dawnward to northward/duskward associated with a parallel current consistent with a brief expansion of the plasma sheet before the front crossing and with a smaller lower hybrid drift wave activity. Electromagnetic electron phase-space holes are detected near these low-frequency drift waves during both events. The drift waves could accelerate electrons parallel to the magnetic field and produce the parallel electron drift needed to generate the electron holes. Yet we cannot rule out the possibility that the drift waves are produced by the antiparallel current associated with the fast flows, leaving the source for the electron holes unexplained.
|
|
| 5. |
- Berger, J. S., et al.
(author)
-
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial
- 2016
-
In: American Heart Journal. - : Elsevier BV. - 0002-8703. ; 175, s. 86-93
-
Journal article (peer-reviewed)abstract
- Background Despite overwhelming data demonstrating the efficacy of antiplatelet therapy in heart disease and stroke, data in peripheral artery disease (PAD) are less compelling. Aspirin has modest evidence supporting a reduction in cardiovascular events in patients with PAD, whereas clopidogrel monotherapy may be more effective in PAD. Ticagrelor, a potent, reversibly binding P2Y(12) receptor antagonist, is beneficial in patients with acute coronary syndrome and prior myocardial infarction. The EUCLID trial is designed to address the need for effective antiplatelet therapy in PAD to decrease the risk of cardiovascular events. Study design EUCLID is a randomized, double-blind, parallel-group, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor compared with clopidogrel for the prevention of major adverse cardiovascular events in subjects with symptomatic PAD. Subjects with established PAD will be randomized in a 1: 1 fashion to ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. The primary end point is a composite of cardiovascular death, myocardial infarction, or ischemic stroke. Other end points address limb events including acute leg ischemia, need for revascularization, disease progression by ankle-brachial index, and quality of life. The primary safety objective is Thrombolysis in Myocardial Infarction-defined major bleeding. Recruitment began in December 2012 and was completed in March 2014; 13,887 patients were randomized. The trial will continue until at least 1,364 adjudicated primary end points occur. Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.
|
|
| 6. |
|
|
| 7. |
- Fuselier, S. A., et al.
(author)
-
Large-scale characteristics of reconnection diffusion regions and associated magnetopause crossings observed by MMS
- 2017
-
In: Journal of Geophysical Research - Space Physics. - 2169-9380 .- 2169-9402. ; 122:5, s. 5466-5486
-
Journal article (peer-reviewed)abstract
- The Magnetospheric Multiscale (MMS) mission was designed to make observations in the very small electron diffusion region (EDR), where magnetic reconnection takes place. From a data set of over 4500 magnetopause crossings obtained in the first phase of the mission, MMS had encounters near or within 12 EDRs. These 12 events and associated magnetopause crossings are considered as a group to determine if they span the widest possible range of external and internal conditions (i.e., in the solar wind and magnetosphere). In addition, observations from MMS are used to determine if there are multiple X-lines present and also to provide information on X-line location relative to the spacecraft. These 12 events represent nearly the widest possible range of conditions at the dayside magnetopause. They occur over a wide range of local times and magnetic shear angles between the magnetosheath and magnetospheric magnetic fields. Most show evidence for multiple reconnection sites.
|
|
| 8. |
- Graham, Daniel B., et al.
(author)
-
Universality of Lower Hybrid Waves at Earth's Magnetopause
- 2019
-
In: Journal of Geophysical Research - Space Physics. - : John Wiley & Sons. - 2169-9380 .- 2169-9402. ; 124:11, s. 8727-8760
-
Journal article (peer-reviewed)abstract
- Waves around the lower hybrid frequency are frequently observed at Earth's magnetopause and readily reach very large amplitudes. Determining the properties of lower hybrid waves is crucial because they are thought to contribute to electron and ion heating, cross‐field particle diffusion, anomalous resistivity, and energy transfer between electrons and ions. All these processes could play an important role in magnetic reconnection at the magnetopause and the evolution of the boundary layer. In this paper, the properties of lower hybrid waves at Earth's magnetopause are investigated using the Magnetospheric Multiscale mission. For the first time, the properties of the waves are investigated using fields and direct particle measurements. The highest‐resolution electron moments resolve the velocity and density fluctuations of lower hybrid waves, confirming that electrons remain approximately frozen in at lower hybrid wave frequencies. Using fields and particle moments, the dispersion relation is constructed and the wave‐normal angle is estimated to be close to 90° to the background magnetic field. The waves are shown to have a finite parallel wave vector, suggesting that they can interact with parallel propagating electrons. The observed wave properties are shown to agree with theoretical predictions, the previously used single‐spacecraft method, and four‐spacecraft timing analyses. These results show that single‐spacecraft methods can accurately determine lower hybrid wave properties.
|
|
| 9. |
- Gunther, M., et al.
(author)
-
Neuroprotective effects of N-acetylcysteine amide on experimental focal penetrating brain injury in rats
- 2015
-
In: Journal of Clinical Neuroscience. - : Elsevier BV. - 0967-5868 .- 1532-2653. ; 22:9, s. 1477-1483
-
Journal article (peer-reviewed)abstract
- We examined the effects of N-acetylcysteine amide (NACA) in the secondary inflammatory response following a novel method of focal penetrating traumatic brain injury (TBI) in rats. N-acetylcysteine (NAC) has limited but well-documented neuroprotective effects after experimental central nervous system ischemia and TBI, but its bioavailability is very low. We tested NACA, a modified form of NAC with higher membrane and blood-brain barrier permeability. Focal penetrating TBI was produced in male Sprague-Dawley rats randomly selected for NACA treatment (n = 5) and no treatment (n = 5). In addition, four animals were submitted to sham surgery. After 2 hours or 24 hours the brains were removed, fresh frozen, cut in 14 mu m coronal sections and subjected to immunohistochemistry, immunofluorescence, Fluoro-Jade and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analyses. All treated animals were given 300 mg/kg NACA intraperitoneally (IP) 2 minutes post trauma. The 24 hour survival group was given an additional bolus of 300 mg/kg IF after 4 hours. NACA treatment decreased neuronal degeneration by Fluoro-Jade at 24 hours with a mean change of 35.0% (p
|
|
| 10. |
- Hess, C. N., et al.
(author)
-
A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative
- 2017
-
In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 0009-7322 .- 1524-4539. ; 135:25, s. 2534-2555
-
Journal article (peer-reviewed)abstract
- Peripheral artery disease affects >200 million people worldwide and is associated with significant limb and cardiovascular morbidity and mortality. Limb revascularization is recommended to improve function and quality of life for symptomatic patients with peripheral artery disease with intermittent claudication who have not responded to medical treatment. For patients with critical limb ischemia, the goals of revascularization are to relieve pain, help wound healing, and prevent limb loss. The baseline risk of cardiovascular and limb-related events demonstrated among patients with stable peripheral artery disease is elevated after revascularization and related to atherothrombosis and restenosis. Both of these processes involve platelet activation and the coagulation cascade, forming the basis for the use of antiplatelet and anticoagulant therapies to optimize procedural success and reduce postprocedural cardiovascular risk. Unfortunately, few high-quality, randomized data to support use of these therapies after peripheral artery disease revascularization exist, and much of the rationale for the use of antiplatelet agents after endovascular peripheral revascularization is extrapolated from percutaneous coronary intervention literature. Consequently, guideline recommendations for antithrombotic therapy after lower limb revascularization are inconsistent and not always evidence-based. In this context, the purpose of this structured review is to assess the available randomized data for antithrombotic therapy after peripheral arterial revascularization, with a focus on clinical trial design issues that may affect interpretation of study results, and highlight areas that require further investigation.
|
|
